Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Gynecologic oncology

Treatment for Locally Advanced and Metastatic Disease

At a Glance

For locally advanced cervical squamous cell carcinoma, treatment often aims to cure by combining external-beam radiation, weekly cisplatin, and brachytherapy within about 7 to 8 weeks; selected patients may also receive pembrolizumab, while metastatic disease generally requires systemic therapy.

When squamous cell carcinoma of the cervix has spread beyond the cervix to nearby tissues or lymph nodes, the goal of treatment remains curative for many patients. This stage of the disease, often called locally advanced (e.g., Stages IB3 through IVA, or node-positive Stage IIIC), requires a highly coordinated combination of radiation, chemotherapy, and sometimes immunotherapy [1][2].

The Foundation: Definitive Chemoradiation

The standard treatment for locally advanced disease is a combination of external-beam radiotherapy (EBRT) and chemotherapy, given at the same time (concurrently) [1].

  • Radiation: EBRT uses high-energy beams to target the pelvis and any involved lymph nodes. Modern techniques like IMRT or VMAT are used to focus the radiation on the tumor while sparing nearby healthy organs like the bladder and bowel [3][4].
  • Chemotherapy: You will typically receive a drug called cisplatin intravenously once a week for 5 to 6 weeks [1]. The chemotherapy acts as a “radiosensitizer,” making the cancer cells more vulnerable to the radiation [5].

Managing Side Effects

Because this treatment is intensive, your medical team will monitor you closely. A common side effect is bone marrow suppression, which can lead to low white blood cell counts (leukopenia or neutropenia) and anemia [4][6]. Cisplatin can also cause kidney injury, electrolyte loss, severe nausea, neuropathy (numbness or tingling), and hearing loss or tinnitus. You will have regular blood tests and kidney function checks before each dose of chemotherapy to ensure it is safe to proceed [1]. Anti-nausea medications and hydration protocols will be provided.

The Essential Component: Brachytherapy

Brachytherapy is an internal form of radiation where a radioactive source is placed temporarily inside the cervix or the tumor itself [1]. It is not an optional “add-on”; it is a critical, standard component of curative treatment. Research shows that omitting brachytherapy significantly compromises the chance of a cure and overall survival [7][8].

Brachytherapy is typically delivered using a specialized applicator inserted under anesthesia or sedation, often with a temporary urinary catheter. Modern care frequently uses image-guided adaptive brachytherapy (using MRI or CT) [9]:

  • Adaptation: The radiation dose is tailored to the exact shape of the tumor as it shrinks during treatment [10].
  • Protection: Healthy tissues like the bladder and rectum are visualized and spared [11].
  • Specialized techniques: If a tumor is large or asymmetric, doctors may use interstitial needles to ensure the radiation reaches all parts of the cancer [12][13].

Timing is critical: The entire course of treatment (EBRT plus brachytherapy) should ideally be completed within 7 to 8 weeks (roughly 56 days) [8][14]. This is a quality target to prevent the cancer from regrowing during breaks, though your team will decide if your individual health requires adjustments [15].

Adding Immunotherapy (Pembrolizumab)

Recent breakthroughs have changed how we treat high-risk, locally advanced disease. A major clinical trial called KEYNOTE-A18 found that adding the immunotherapy drug pembrolizumab to standard chemoradiation improves outcomes for eligible patients [6][2].

In this trial, patients received pembrolizumab alongside their weekly cisplatin and radiation, followed by maintenance pembrolizumab for up to roughly two years total [6]. The results showed:

  • Better disease control: At two years, 68% of patients receiving pembrolizumab were alive without disease progression, compared to 57% who received only chemoradiation [2].

Pembrolizumab is not universally required; eligibility depends on your exact stage, nodal status, and local guidelines. While this combination is effective for those who meet the criteria, it does increase the risk of immune-mediated side effects, so your team will monitor your thyroid, lungs, bowel, liver, and other organs closely [6][16].

Managing Metastatic Disease (Stage IVB)

If the cancer has spread to distant organs like the lungs or liver, it is considered metastatic (Stage IVB). Treatment at this stage primarily focuses on systemic therapy (such as a platinum-taxane chemotherapy combination, often with targeted therapies like bevacizumab or immunotherapies like pembrolizumab, depending on your tumor’s PD-L1 status) that travels through the whole body [17]. The goals here may be disease-controlling or palliative, integrating symptom control and supportive care from the start.

However, for a highly selected subset of patients with oligometastatic disease—meaning only a few isolated spots of cancer have spread—multidisciplinary doctors may still pursue a strategy targeting the primary tumor in the cervix with standard chemoradiation [18], while targeting the distant spots with surgery or SBRT (Stereotactic Body Radiotherapy) [19][20]. This is a specialized approach with less certain evidence, but it has shown the potential for disease control in appropriate individuals [18][21].

Common questions in this guide

What is the usual treatment for locally advanced cervical cancer?
The standard approach is external-beam radiation to the pelvis and involved lymph nodes given at the same time as weekly cisplatin chemotherapy. The treatment course also includes brachytherapy, an internal form of radiation that is an essential part of treatment intended to cure many patients.
Why is brachytherapy important for cervical cancer?
Brachytherapy places a radioactive source temporarily inside the cervix or tumor so a focused dose reaches the cancer while nearby organs are protected. It is a critical component of curative treatment, and leaving it out can substantially reduce the chance of cure and overall survival.
How long does treatment for locally advanced cervical cancer take?
The combined course of external-beam radiation and brachytherapy should ideally be completed within 7 to 8 weeks, or about 56 days. The schedule may be adjusted if your health or treatment needs require it, so your team will monitor timing closely.
Who may receive pembrolizumab with chemoradiation?
Pembrolizumab may be offered to some patients with high-risk, locally advanced cervical cancer based on the cancer’s stage, lymph-node involvement, and local treatment guidelines. It may be given with radiation and weekly cisplatin, followed by maintenance treatment for up to about two years, with monitoring for immune-related side effects.
What side effects are monitored during weekly cisplatin treatment?
Cisplatin can affect kidney function, electrolytes, blood counts, hearing, nerves, and nausea. Before doses, your care team uses blood tests and kidney checks and may provide hydration and anti-nausea medicine; report new numbness, ringing in the ears, or other concerning symptoms.
What happens during image-guided brachytherapy?
A specialized applicator is placed under anesthesia or sedation, often with a temporary urinary catheter. MRI or CT helps the team tailor the radiation dose and protect the bladder and rectum, while interstitial needles may be used for a large or unevenly shaped tumor.
How is metastatic cervical cancer treated?
When cervical cancer has spread to distant organs, treatment usually centers on systemic therapy, such as a platinum-taxane combination with or without bevacizumab or pembrolizumab, depending partly on PD-L1 status. Symptom relief and supportive care are included from the start, and selected patients with only a few distant spots may also be considered for surgery or focused radiation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a candidate for the addition of pembrolizumab based on my specific stage and risk factors?
  2. 2.What is the plan to ensure my chemoradiation and brachytherapy are completed within the recommended window?
  3. 3.Will we be using MRI or CT-guided adaptive brachytherapy, and what should I expect regarding anesthesia and recovery?
  4. 4.What specific criteria will you use to monitor my kidney function, electrolytes, and hearing during my weekly cisplatin treatments?
  5. 5.If I have oligometastatic disease, what is the multidisciplinary plan regarding systemic therapy and local radiation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.

    Pötter R, Tanderup K, Schmid MP, et al.

    The Lancet. Oncology 2021; (22(4)):538-547 doi:10.1016/S1470-2045(20)30753-1.

    PMID: 33794207
  2. 2

    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.

    Lorusso D, Xiang Y, Hasegawa K, et al.

    Lancet (London, England) 2024; (403(10434)):1341-1350 doi:10.1016/S0140-6736(24)00317-9.

    PMID: 38521086
  3. 3

    Refinement in radiotherapy treatment for locally advanced cervical cancer: a historic perspective.

    Caicedo-Martínez M, Arbeláez-Mariño AF, Arbeláez L, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2026; 102878 doi:10.1016/j.ijgc.2025.102878.

    PMID: 41775566
  4. 4

    Outcome and toxicity of chemoradiation using volumetric modulated arc therapy followed by 3D image-guided brachytherapy for cervical cancer: Vietnam National Cancer Hospital experience.

    Van Anh DT, Thang VH, Dung TA, et al.

    Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology 2023; (28(6)):784-793 doi:10.5603/rpor.98735.

    PMID: 38515819
  5. 5

    Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.

    Wang W, Hou X, Yan J, et al.

    BMC cancer 2017; (17(1)):510 doi:10.1186/s12885-017-3503-2.

    PMID: 28764676
  6. 6

    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

    Lorusso D, Xiang Y, Hasegawa K, et al.

    Lancet (London, England) 2024; (404(10460)):1321-1332 doi:10.1016/S0140-6736(24)01808-7.

    PMID: 39288779
  7. 7

    Differences in outcome for cervical cancer patients treated with or without brachytherapy.

    Karlsson J, Dreifaldt AC, Mordhorst LB, Sorbe B

    Brachytherapy 2017; (16(1)):133-140 doi:10.1016/j.brachy.2016.09.011.

    PMID: 27836496
  8. 8

    Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer.

    Korenaga TK, Yoshida EJ, Pierson W, et al.

    Gynecologic oncology 2022; (164(2)):348-356 doi:10.1016/j.ygyno.2021.11.015.

    PMID: 34865860
  9. 9

    Comparative Outcomes of Survival and Relapse After High-Dose-Rate Brachytherapy Versus External-Beam Radiotherapy Boost Following Concurrent Chemoradiation in Locally Advanced Cervical Cancer in Algeria.

    Benarbia M, Boukerche A

    JCO global oncology 2026; (12(4)):e2500664 doi:10.1200/GO-25-00664.

    PMID: 42024843
  10. 10

    MRI-based image-guided adaptive brachytherapy for locally advanced cervical cancer in clinical routine: a single-institution experience.

    Végváry Z, Kószó R, Együd Z, et al.

    Pathology oncology research : POR 2025; (31()):1612077 doi:10.3389/pore.2025.1612077.

    PMID: 40376012
  11. 11

    Magnetic Resonance Imaging-Guided Adaptive Brachytherapy for the Treatment of Cervical Cancer and its Impact on Clinical Outcome.

    Singhal S, Veeratterapillay J, Locks S, et al.

    Clinical oncology (Royal College of Radiologists (Great Britain)) 2022; (34(7)):442-451 doi:10.1016/j.clon.2022.01.039.

    PMID: 35123850
  12. 12

    MRI-Directed Brachytherapy for Cancer of the Uterine Cervix: A Case Report, Review, and Perspective on the Importance of Widespread Use of This Technological Advance in the United States.

    Ahmed HZ, Vijayakumar S, Duggar WN, Allbright R

    Cureus 2021; (13(6)):e15495 doi:10.7759/cureus.15495.

    PMID: 34113529
  13. 13

    Brachytherapy use in cervical cancer: a narrative review.

    Moorthy A, Le NA, Issac A, et al.

    Gynecology and pelvic medicine 2026; (9()):8 doi:10.21037/gpm-25-44.

    PMID: 42212287
  14. 14

    Clinical Outcomes and Prognostic Factors Following Routine CT-Based Image-Guided Adaptive Brachytherapy for Cervical Cancer: A Retrospective Cohort Study.

    Muangwong P, Tharavichitkul E, Chakrabandhu S, et al.

    Cancers 2026; (18(17)) doi:10.3390/cancers18172805.

    PMID: 42738326
  15. 15

    Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer.

    Tanderup K, Fokdal LU, Sturdza A, et al.

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2016; (120(3)):441-446 doi:10.1016/j.radonc.2016.05.014.

    PMID: 27350396
  16. 16

    Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.

    Randall L, Xiang Y, Matsumoto T, et al.

    Gynecologic oncology 2025; (199()):88-95 doi:10.1016/j.ygyno.2025.06.003.

    PMID: 40592026
  17. 17

    The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0).

    Sznurkowski JJ, Bodnar L, Szylberg Ł, et al.

    Journal of clinical medicine 2024; (13(15)) doi:10.3390/jcm13154351.

    PMID: 39124620
  18. 18

    Definitive irradiation as a first treatment strategy for primary and metastatic sites of newly diagnosed IVB cervical cancer that presented with synchronous oligometastases.

    Li J, Wang Y, Huo L, et al.

    Radiation oncology (London, England) 2023; (18(1)):159 doi:10.1186/s13014-023-02320-6.

    PMID: 37752606
  19. 19

    Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer.

    Ning MS, Ahobila V, Jhingran A, et al.

    Gynecologic oncology 2018; (148(1)):132-138 doi:10.1016/j.ygyno.2017.10.017.

    PMID: 29089122
  20. 20

    Impact of high-dose pelvic radiotherapy combined with chemotherapy on local control, symptom relief, and safety in patients with stage IVB cervical cancer (FIGO 2018): a two-center retrospective study.

    Nakashima T, Matsumoto K, Yoshitake T, et al.

    Japanese journal of radiology 2026; (44(4)):719-729 doi:10.1007/s11604-025-01923-1.

    PMID: 41441948
  21. 21

    Prognostic Factors and Treatment Outcome for Patients with Stage IVB Cervical Cancer.

    Oishi S, Kudaka W, Toita T, et al.

    Anticancer research 2016; (36(7)):3471-5.

    PMID: 27354610

This page explains treatment options for advanced cervical squamous cell carcinoma for informational purposes only and does not replace medical advice. Your gynecologic oncology team can tailor treatment and monitoring to your stage and health.

Get notified when new evidence is published on Squamous cell carcinoma of the cervix uteri.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.